Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target Lowered to $70.00 at Leerink Partners

Ultragenyx Pharmaceutical (NASDAQ:RARE) had its target price reduced by Leerink Partners from $80.00 to $70.00 in a report released on Tuesday,Benzinga reports. They currently have an outperform rating on the biopharmaceutical company’s stock.

A number of other brokerages have also recently weighed in on RARE. Truist Financial dropped their price objective on shares of Ultragenyx Pharmaceutical from $100.00 to $90.00 and set a “buy” rating for the company in a research note on Wednesday, November 5th. TD Cowen decreased their price objective on Ultragenyx Pharmaceutical from $86.00 to $75.00 and set a “buy” rating on the stock in a research note on Wednesday, November 5th. Wells Fargo & Company cut their target price on shares of Ultragenyx Pharmaceutical from $65.00 to $45.00 and set an “overweight” rating for the company in a research note on Tuesday. Jefferies Financial Group reduced their target price on shares of Ultragenyx Pharmaceutical from $114.00 to $63.00 and set a “buy” rating on the stock in a report on Tuesday. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, October 8th. Fifteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $75.19.

Ultragenyx Pharmaceutical Stock Performance

Ultragenyx Pharmaceutical stock opened at $22.78 on Tuesday. Ultragenyx Pharmaceutical has a fifty-two week low of $18.41 and a fifty-two week high of $46.50. The stock’s fifty day moving average is $33.43 and its two-hundred day moving average is $32.01. The firm has a market capitalization of $2.20 billion, a price-to-earnings ratio of -3.84 and a beta of 0.16.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported ($1.81) EPS for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.58). Ultragenyx Pharmaceutical had a negative net margin of 91.95% and a negative return on equity of 414.17%. The business had revenue of $159.93 million during the quarter, compared to analyst estimates of $167.42 million. During the same period in the previous year, the company posted ($1.40) earnings per share. Ultragenyx Pharmaceutical’s revenue was up 14.6% on a year-over-year basis. As a group, sell-side analysts forecast that Ultragenyx Pharmaceutical will post -5.18 EPS for the current fiscal year.

Insider Transactions at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 3,081 shares of the firm’s stock in a transaction dated Wednesday, December 10th. The stock was sold at an average price of $36.38, for a total value of $112,086.78. Following the transaction, the chief financial officer directly owned 95,146 shares of the company’s stock, valued at $3,461,411.48. This trade represents a 3.14% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In the last three months, insiders sold 11,108 shares of company stock valued at $365,262. 5.50% of the stock is currently owned by corporate insiders.

Institutional Trading of Ultragenyx Pharmaceutical

Hedge funds have recently made changes to their positions in the company. Parallel Advisors LLC boosted its stake in shares of Ultragenyx Pharmaceutical by 1,061.9% in the second quarter. Parallel Advisors LLC now owns 732 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 669 shares during the period. Assetmark Inc. lifted its holdings in Ultragenyx Pharmaceutical by 1,706.7% in the 3rd quarter. Assetmark Inc. now owns 1,084 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 1,024 shares in the last quarter. Huntington National Bank boosted its position in Ultragenyx Pharmaceutical by 56.2% in the 3rd quarter. Huntington National Bank now owns 1,092 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 393 shares during the last quarter. Danske Bank A S purchased a new position in Ultragenyx Pharmaceutical in the 3rd quarter valued at about $39,000. Finally, Smartleaf Asset Management LLC grew its stake in shares of Ultragenyx Pharmaceutical by 205.4% during the third quarter. Smartleaf Asset Management LLC now owns 1,738 shares of the biopharmaceutical company’s stock valued at $53,000 after acquiring an additional 1,169 shares in the last quarter. Hedge funds and other institutional investors own 97.67% of the company’s stock.

Key Headlines Impacting Ultragenyx Pharmaceutical

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Ultragenyx completed the rolling BLA submission to the FDA for DTX401 (pariglasgene brecaparvovec) for GSDIa — the filing now includes CMC, clinical and non‑clinical modules; the program has RMAT/ Fast Track/orphan designations and Phase 3 data across ~52 patients showing reduced cornstarch use and improved glycemic control. This is a multi‑year commercial catalyst if approved and would be the first therapy addressing the underlying cause of GSDIa. GlobeNewswire: BLA Submission
• Positive Sentiment: Unusual options activity: an above‑average number of call contracts traded, indicating speculative/hedged bullish interest that may amplify intraday upside.
• Neutral Sentiment: Analysts revised price targets lower after the recent volatility but largely maintained Outperform/Buy ratings (examples: Baird, Leerink, Jefferies, Wells Fargo), leaving materially higher median targets than the current price — reflects confidence in longer‑term pipeline value but acknowledges near‑term uncertainty. Benzinga: Analyst Moves
• Neutral Sentiment: Small insider sale disclosed (CAO sold 85 shares) — immaterial to ownership but noted by market participants. SEC filing: SEC Filing
• Negative Sentiment: Major negative catalyst: Ultragenyx and partner Mereo announced that two Phase 3 studies of setrusumab in osteogenesis imperfecta failed to meet primary endpoints (no reduction in fracture rate), which precipitated a steep market decline and prompted operational retrenchment announcements. This materially reduces near‑term revenue prospects and created significant investor uncertainty. Reuters: Setrusumab Phase 3 Failure
• Negative Sentiment: Two law firms (Pomerantz, Portnoy) announced investigations into Ultragenyx that may lead to securities litigation related to the trial misses and disclosures — potential legal overhang and expense risk. GlobeNewswire: Pomerantz GlobeNewswire: Portnoy
• Negative Sentiment: Market mechanics: trading was halted as key news hit and the shares experienced extreme intraday volatility and high volume, reflecting rapid re‑pricing and elevated risk for short‑term holders. Coverage and headlines amplified the selloff. MarketWatch: Shares Slide

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.